A novel flow cytometric assay for rapid detection of extended-spectrum beta-lactamases  by Faria-Ramos, I. et al.
A novel ﬂow cytometric assay for rapid detection of extended-spectrum
beta-lactamases
I. Faria-Ramos1, M. J. Espinar1,2,3, R. Rocha1, J. Santos-Antunes1,4, A. G. Rodrigues1,2, R. Canto´n5,6 and C. Pina-Vaz1,2,3
1) Department of Microbiology, Faculty of Medicine, University of Porto, Porto, 2) Cardiovascular Research and Development Unit, Faculty of Medicine, Uni-
versity of Porto, Porto, 3) Department of Microbiology, Hospital S. Joa˜o, Porto, Portugal, 4) Gastroenterology Department, Hospital S. Joa˜o, Porto, Portugal,
5) Servicio de Microbiologı´a and CIBER en Epidemiologı´a y Salud Pu´blica (CIBERESP), Instituto Ramo´n y Cajal de Investigacio´n Sanitaria (IRYCIS) and Hospi-
tal Universitario Ramo´n y Cajal, Madrid and 6) Unidad de Resistencia a Antibio´ticos y Virulencia Bacteriana asociada al Consejo Superior de Investigaciones
Cientı´ﬁcas (CSIC), Madrid, Spain
Abstract
The rapid detection of extended-spectrum beta-lactamases (ESBLs) is a challenge for most clinical microbiology laboratories because inac-
curate identiﬁcation of ESBL producers has important clinical implications for both antibiotic treatment and infection control. The aim of
our study was to develop a rapid detection assay of ESBL producers based upon ﬂow cytometric analysis. Antimicrobial susceptibility testing
followed by molecular characterization of blaTEM, blaSHV or blaCTX-M genes was performed on clinical isolates (41 ESBL positive and 20 ESBL
negative) and isolates expressing well-characterized beta-lactamases, including ESBLs (n = 13), plasmid AmpCs (n = 3), oxacillinases (n = 5)
and carbapenemases (n = 3). Additionally, two ATCC strains recommended by CLSI for susceptibility testing were used as controls. The
ﬂow cytometry analysis protocol involved an incubation of bacterial cells with different concentrations of ceftazidime (1, 2 and 4 mg/L) and
cefotaxime (4, 8 and 16 mg/L) for 1 and 2 hours, in the presence and absence of clavulanic acid; subsequently, cells were stained with the
ﬂuorescent dye Bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)], a lipophilic anion able to diffuse across depolarized mem-
branes. Additionally, CFU counts were performed. Susceptible isolates displayed increased ﬂuorescence after 1 hour of incubation; con-
versely, the increase of the depolarized population was only observed after incubation with clavulanic acid associated with ceftazidime or
cefotaxime in ESBL producers. An excellent correlation was obtained between the number of non-depolarized bacteria quantiﬁed by ﬂow
cytometry and by conventional CFU assays. A novel, accurate and fast ﬂow cytometric assay is available to detect the presence of ESBLs.
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Introduction
Extended-spectrum beta-lactamases (ESBLs) are a large and
rapidly evolving group of plasmid-mediated enzymes that con-
fer resistance to oxyimino-cephalosporins and monobactams.
These drugs are widely used for the treatment of serious inva-
sive infections by Gram-negative bacteria [1]. ESBL recognition
has an important clinical impact as inappropriate treatment can
lead to therapeutic failures and consequently to adverse clinical
outcomes [2]. Furthermore, failure to rapidly and reliably
detect ESBL-producing isolates may impair appropriate infec-
tion control measures, which further contributes to its diffu-
sion. Rapid detection of ESBL producers may not be easy and
readily available during routine susceptibility testing because
conﬁrmation methods are often necessary. The semi-auto-
mated systems used by most clinical laboratories vary consid-
erably regarding the detection capacity of ESBLs [1–3]. This
detection has been invariably based upon growth assessment
in the presence of cephalosporins with and without CLA.
On the other hand, although molecular methods brought
speed and accuracy, several drawbacks prevent their full use
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for ESBL diagnosis. DNA microarrays and multiplex PCR
assays aiming to detect the most prevalent ESBL genes in the
clinical setting, namely TEM, SHV and CTX-M, have been
developed and are commercially available [4–6]. However,
the genes encoding ESBL enzymes are highly diverse due to
a variable number of amino acid substitutions as a result of
continuous mutation. This contributes to the high cost of
molecular assays. Moreover, although they provide valuable
information for ESBL epidemiological investigation, pheno-
type tests could have a wider spectrum, making them more
adequate for clinical use.
In order to cope with ESBL diversity, a comprehensive set
of molecularly well-characterized isolates were hereby stud-
ied by classic methods and by ﬂow cytometry (FC) assay. FC
is a rapid, powerful high-throughput technology, which allows
the analysis of several thousand cells per second, providing
quantitative and statistically signiﬁcant data [7]. Our group
has developed several FC microbiological applications,
namely to characterize and distinguish different physiological
states of microorganisms, which could be addressed in rela-
tion to antibiotic susceptibility [8–11]. In the present study,
an FC assay for the detection of ESBL producers is pro-
posed. This method represents progress when comparing it
with the conventional procedures.
Material and Methods
Bacterial strains
A total of 61 clinical isolates (64% from intensive care units)
were tested; 20 ESBL-negative and 41 ESBL-positive isolates.
All ESBL producers were resistant to cefotaxime and/or ceft-
azidime. Additionally, isolates expressing well-characterized
beta-lactamases were also included in order to determine
the true speciﬁcity of the cytometric assay (Table 1). Two
strains from the American Type Culture Collection (ATCC),
(Klebsiella pneumoniae ATCC 700603 and Escherichia coli
ATCC 25922) recommended by the CLSI for susceptibility
testing were used as controls [12].
Antimicrobial drugs and ESBL phenotypic detection
Ceftazidime (CAZ), cefotaxime (CTX) and CLA were pur-
chased from Sigma Chemical Company (St Louis, MO, USA).
Stock solutions (10 mg/ml) were prepared in sterile distilled
water. Bis-(1,3-dibutylbarbituric acid) trimethine oxonol
[DiBAC4(3)], a ﬂuorescent probe that binds to membranes
and to intracellular proteins of depolarized cells, was pur-
chased from Sigma Chemical Company; a stock solution
(1 mg/ml) was prepared in dimethyl sulphoxide (DMSO).
The evaluation of the susceptibility proﬁle to common
cephalosporins and a screening for ESBL producers was con-
ducted with VITEK 2 System panel AST-151 (BioMe´rieux,
Paris, France). The disc diffusion method, using CAZ (30 lg)
and CTX (30 lg) with and without CLA (10 lg), was used
as a conﬁrmatory test in isolates classiﬁed by the automated
system as ESBL producers. The CLSI M2-A10 protocol was
followed [13].
Multiplex PCR assay for ESBL characterization
A multiplex PCR protocol was used for the most common
ESBL genes (TEM, SHV and CTX-M) according to Espinar
and colleagues [14].
Flow cytometric analysis
The bacterial strains were incubated at 35 ± 1C with shak-
ing in Mu¨eller-Hinton broth (DifcoTM) until the log phase
was reached (about 1 h and 15 mins). Subsequently, a sus-
pension containing 5 · 106 cells/ml in fresh medium was pre-
pared and the bacterial cells were exposed either to 1, 2
and 4 mg/L of CTX, or 4, 8 and 16 mg/L of CAZ, alone or
with 4 mg/L of CLA, for 60 and 120 min. In parallel, similar
incubations with antimicrobials were performed after prepar-
ing bacterial suspensions directly from 24-h colonies. After
incubation, the cells were washed and stained with 1 mg/L
DiBAC4(3) for 30 min, at room temperature, protected from
light. For each strain, non-treated and non-stained cells were
also analysed in order to evaluate the native cell autoﬂuores-
cence.
The ﬂuorescence of bacterial suspensions was measured on
a FACSCalibur Cytometer (BD Biosciences, Sydney,
Australia). The data generated by FC were analyzed by CELL
QUEST PRO software (version 4.0.2, BD Biosciences). The acqui-
sition settings were deﬁned using non-treated and non-stained
cells (autoﬂuorescence) and after adjusting the PMTs voltage
to the ﬁrst logarithmic (log) decade. The ﬂuorescence intensity
at 530/30 nm (FL1) was registered after incubation with anti-
microbials and staining with 1 mg/L DiBAC4(3); the percentage
of depolarized cells (cells with high intensity of green ﬂuores-
cence) was quantiﬁed based upon the gated population and
the area under the obtained curve, which is automatically nor-
malized by the CYTOMETER software.
Cytometric susceptibility phenotype to cephalosporins and
CLA Index
According to the results of the percentage of depolarized
cells of each isolate after incubation with the cephalosporin,
a cut-off value was deﬁned in order to classify them as sus-
ceptible or resistant. In order to evaluate the CLA effect on
resistant strains, a CLA index was calculated as the ratio of
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the percentage of depolarized cells (cells with high intensity
of ﬂuorescence) after treatment with 4 mg/L of CTX or with
16 mg/L of CAZ in the presence vs. absence of CLA.
Viability
The number of CFU per ml following incubation with the anti-
microbials was estimated using the technique of Miles et al.
[15].
Statistical analysis
Statistical analysis was performed with SPSS software version
21.0 (SPSS Inc., Chicago, IL, USA). Continuous and indepen-
dent variables were compared using Student t-test to analyse
the signiﬁcance of the differences in the susceptibility pattern
displayed by the studied group of strains, analysed by FC. In
parallel, the same analysis was performed for the viability
counts. A p value <0.05 was considered signiﬁcant with a
conﬁdence interval of 95%.
Results
Phenotypic and molecular strain characterization
Phenotypic tests classiﬁed the clinical isolates as ESBL posi-
tive (n = 41) or negative (n = 20) and the control strains as
expected. The molecular results of the ESBL-positive set of
strains revealed a great heterogeneity. Several strains reveal
more than one putative ESBL gene (Table 1). Molecular char-
acteristics of isolates with well-characterized resistance
mechanisms are included in Table 1.
TABLE 1. Characterization of the tested isolates according to the susceptibility phenotype, biomolecular proﬁle and ﬂow
cytometry analysis after staining with DiBAC4(3)
Flow Cytometry*
BioMolecular
characterization
% depolarized
cells with CTX
CLA Index
CTX
% depolarized cells
with CAZ
CLA Index
CAZ
Genotyped strains
Class A CTX-M beta-lactamases CTX-M-1 9.67 1.6 12.31 10.7
CTX-M-2 4.88 5.7 8.93 13.1
CTX-M-3 7.49 3.9 9.04 14.7
1UCCTX-M-8 2.85 6.1 11.87 9.8
CTX-M-9 6.57 11.8 9.34 2.6
CTX-M-10 2.38 9.3 10.05 3.3
CTX-M-14b 2.51 4.6 9.93 12.4
CTX-M-15 1.55 12.8 3.71 19.2
Class A TEM beta-lactamases TEM-4 12.53 6.2 5.97 3.7
TEM-24 9.62 5.4 9.76 4.6
Class A SHV beta-lactamases SHV-2 5.23 19.7 28.5 8.7
SHV-5 8.75 7.3 7.12 2.4
SHV-12 3.24 7.1 2.59 3.8
Class A carbapenemases KPC 5.61 1.0 3.92 1.4
KPC + CTX-M and SHV 7.89 5.2 8.83 1.6
Inhibitor resistant beta-lactamases
Class C AmpC beta-lactamases FOX-5 6.78 0.2 5.34 0.1
ACT-1 7.01 0.4 9.32 0
DHA-1 8.87 0 6.47 0.1
Class D Penicillinases OXA-1 0.4 0.3 0 0
OXA-2 3.7 0 4.88 0.6
OXA-3 1.2 0.1 0.5 0
OXA-4 7.63 0 2.36 0.3
OXA-7 8.46 0 2.43 0.5
Class B carbapenemases VIM 9.98 0.1 10.23 0
Clinical isolatesa (61 – no. of isolates)
ESBL positive (41)
K. pneumoniae (18) SHV, TEM and CTX-M (4) 10.02 24.1 0.26 12.4
CTX-M and SHV (3) 9.73 3.0 9.35 4.8
SHV and TEM (1) 8.70 2.6 4.29 6.5
TEM (3) 7.55 5.6 1.28 1.5
SHV (7) 0.61 3.7 2.28 3.4
E. coli (23) TEM and SHV (4) 0.41 2.8 1.95 3.2
CTX-M and SHV (4) 7.39 3.1 7.28 6.6
TEM (4) 2.98 4.1 3.24 6.4
CTX-M (6) 5.24 2.3 0.57 2.9
SHV (5) 8.02 4.2 2.17 7.7
ESBL negative (20)
K. pneumoniae (8) – 79.22 0.8 77.41 1.2
E. coli (12) – 52.93 1.0 49.89 1.3
*Percentage of depolarized cells (stained by DiBAC4(3)) following treatment with 4 mg/L of cefotaxime (CTX) and 16 mg/L of ceftazidime (CAZ); the CLA Index was calcu-
lated for each of the two cephalosporins.
aFor clinical isolates mean values are shown for the ﬂuorescence intensity
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Flow cytometric ESBL phenotype
The typical ﬂuorescence distribution of a bacterial population
is depicted in Fig. 1(a). The autoﬂuorescence signal was
always detected at the ﬁrst decade of the logarithmic scale,
which corresponds to very low ﬂuorescence intensity. Thus,
the intrinsic autoﬂuorescence of bacterial cells does not
interfere with the assessment of membrane depolarization by
FC using DIBAC4 (3) as a voltage sensor probe. Higher
intensity of green ﬂuorescence (530/30 nm - FL1) was
obtained with dead cells compared with non-treated (viable)
cells; consequently, two distinct regions were deﬁned,
respectively, for depolarized and polarized cells after staining
with DIBAC4(3). The damaging impact of cephalosporins
upon the bacterial membrane potential was only registered
with cells growing in the late log phase (broth culture) (i.e.
cells that are rapidly dividing). Considering stationary growth
phase cells (plate culture), both compounds tested (CAZ and
CTX) were not effective. The cephalosporin-resistant strains
showed a ﬂuorescence proﬁle identical to the viable control
(non-treated cells) (Fig. 1d, e); only 10% of the bacterial cell
population was detected in the region corresponding to
depolarized cells, following incubation with 1 mg/L of CTX
or 4 mg/L CAZ for 60 min. Similar results were obtained
with 120 min (data not shown). The number of depolarized
cells slightly increased (to no more than 20% of the popula-
tion) with higher concentrations of cephalosporin (namely,
4 mg/L of CTX and 16 mg/L of CAZ) (Fig. 1d, e). Therefore,
the optimal conditions were 4 mg/L of CTX and 16 mg/L of
CAZ, both with 1 h of incubation. Nevertheless, the differ-
entiation between the susceptible (Fig. 1b, c) and cephalo-
sporin-resistant (Fig. 1d, e) phenotype based upon
ﬂuorescence distribution could be reliably achieved
(p <0.0001).
Considering the ESBL-positive clinical isolates, the per-
centage of depolarized cells drastically increased following
simultaneous incubation both with CLA and cephalosporin,
even at the lowest concentrations (1 mg/L of CTX or 4 mg/
L of CAZ) (Fig. 1f, i). Nevertheless, a small population of
bacteria still remained polarized at this concentration, corre-
sponding to <20%. This ﬁnding occurred with both cephalo-
sporins tested. Interestingly, when testing higher
cephalosporin concentrations, the cell population became
totally depolarized; indeed, it resulted in the displacement of
the ﬂuorescence peak to the extreme right of the histogram
(Fig. 1f–k). For that reason, the CLA Index was calculated
for the highest concentration of CAZ and of CTX. Because
the CLA Index deﬁnes the ratio between the percentage of
depolarized cells after treatment with each cephalosporin
plus 4 mg/L of CLA and the percentage of depolarized cells
after treatment just with each cephalosporin alone, we were
able to discriminate accurately ESBL producers among cepha-
losporin-resistant strains. Using the ESBL detection cytomet-
ric protocol described above, the percentage of polarized vs.
depolarized cell populations was statistically different for
ESBL-positive strains (p <0.001).
The deﬁnition of ESBL positivity based upon CAZ or CTX
resistance and synergy with CLA had been previously estab-
lished in the conﬁrmatory disc diffusion test [13]. Taking into
account the suggested CLA Index, all 41 ESBL-positive clini-
cal strains exhibited values higher than 1.5 for at least one
cephalosporin. This CLA Index ranged from 1.5 to 28.5
(Table 1), the absolute value being not related to the ESBL
genotype (i.e. the type of b-lactamase expressed). As
expected, in susceptible strains the CLA index was lower
than 1.5, ranging from 0.8 to 1.2. As a result, we used the
>1.5 CLA Index for at least one cephalosporin criteria to
categorize a strain as ESBL positive.
As expected, considering collection strains with well-char-
acterized genotypes, two patterns were observed. The ﬁrst
pattern corresponded to isolates harbouring ESBL (Class A
CTX-M, TEM and SHV beta-lactamases) encoding genes that
were resistant to at least one cephalosporin and were inhib-
ited by CLA and isolates harbouring Class A Carbapenemas-
es of the KPC category, which, despite not being an ESBL, is
partially inhibited by CLA. The second pattern was exhibited
with those isolates expressing beta-lactamases that belong to
Class C (plasmid AmpC beta-lactamases: FOX-5, ACT-1,
DHA-1), Class D Penicillinases (OXA enzymes) and Class B
Carbapenemases (VIM enzyme), which were resistant to the
studied cephalosporin and were not inhibited by CLA. Both
patterns presented a minimal percentage of cells exhibiting
membrane depolarization (always <10%) after incubation
with each cephalosporin; conversely, after its simultaneous
incubation with CLA only the second pattern maintained the
same minimal percentage of membrane depolarization, while
the ﬁrst pattern showed almost all cells depolarized
(p >0.05). Accordingly, the CLA index obtained for the ﬁrst
pattern was higher than 1.5, while it was lower than 1.5 for
the second pattern.
Cell viability
In order to conﬁrm that the depolarized bacterial cells were
non-viable, the percentage of viable cells assessed by FC was
compared with the corresponding number of CFU (Fig. 2).
Cephalosporin-susceptible strains showed a dramatic reduc-
tion of CFU counts after incubation for 60 min with CAZ
(92.9%) or CTX (96.8%), corresponding to depolarized cells
according to ﬂow cytometric analysis. This decrease was
more evident with CTX than with CAZ, but nevertheless
remained unchanged by the presence of CLA. Conversely,
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(a)
(f)
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(h)
(i)
(j)
(k)
(b)
(c)
(d)
(e)
FIG. 1. Flow cytometric histograms repre-
senting the emitted ﬂuorescence at FL1 (green
- 530 nm) of the bacterial population. (a) Con-
trol - 106 bacterial cells per ml: (a) autoﬂuo-
rescence, (b) viable (non-treated) and (c) dead
cells both stained with Bis-(1,3-dibutylbarbitu-
ric acid) trimethine oxonol (DiBAC4(3)). Typi-
cal example of extended-spectrum beta-
lactamases (ESBL)-negative strains, susceptible
(b), (d) and resistant (e), (f) to cefotaxime
(CTX) and ceftazidime (CAZ), with and with-
out clavulanic acid (CLA) at 4 mg/L. Typical
example of ESBL-positive isolate after treat-
ment with CTX at 1, 2, 4 mg/L – (f), (g), (h),
respectively, and CAZ at 4, 8 and 16 mg/L –
(i),(j),(k), respectively, with and without CLA
at 4 mg/L.
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ESBL-positive strains showed a reduction of the number of
CFU only when the cephalosporin was associated with CLA.
As shown by FC, CLA promotes the efﬁcacy of low cephalo-
sporin concentrations, resulting in cell depolarization and
therefore in an evident reduction of CFU counts, compared
with the single effect of cephalosporin.
Discussion
The alarming rise of ESBL producing organisms imposes
increasing challenges for their detection as well as for imple-
mentation of infection control programmes. The current
available phenotypic diagnostic methods take too much time
to provide results. Our assay, mimicking the classic method,
is based upon the determination of antibiotic susceptibility
following incubation of cephalosporin in the presence of
CLA. This is a novel ﬂow cytometric protocol to detect
ESBL-producing strains. This methodology provides a rapid
and accurate analysis of many individual bacteria within a
large population and showed excellent correlation either
with phenotypic analysis or molecular typing. All the 41 clini-
cal isolates previously phenotypically catalogued by the con-
ﬁrmatory method recommended by CLSI (disc diffusion
assay) as ESBL positive were correctly detected by FC analy-
sis following staining with DIBAC4(3). Hence, DiBAC4(3) was
found to be a sensitive probe for assessing the impairment
of cell membrane potential resulting from cephalosporin
action. Positive FC results were obtained irrespective of
ESBL type. Interestingly, despite the presence of multiple
b-lactamases genes, a fact earlier described as impairing the
effectiveness of the b-lactamase inhibitor CLA, the FC detec-
tion of ESBL-positive strains was highly successful. Neverthe-
less, false negative results might be obtained whenever rare
ESBL types are present, because they are not inhibited by
CLA [16]. False negative results could be also expected with
isolates expressing enzymes (Complex Mutant TEM), which
confer resistance to cephalosporins but are partially inhibited
by CLA [17].
In order to assess the true speciﬁcity of the method
hereby reported, isolates with beta-lactamases other than
ESBLs, such as VIM (class B carbapenemase), OXA (class D
penicillinases) and DHA-1 (class C AmpC beta-lactamases),
which are not inhibited by CLA (CLA index < 1.5), were
tested [18]. Moreover, class A carbapenemases, KPC, par-
tially inhibited by CLA were also included. Additionally, it is
to be emphasized that multidrug-resistant bacteria often pro-
duce different beta-lactamases, including an ESBL, a carbape-
nemase and/or a high-level cephalosporinase. Two KPC
strains were selected; one of them co-producing an ESBL
and the other one without this enzyme. Interestingly, the
KPC-positive but ESBL-negative isolate was negative in our
FC assay, contrary to that observed with the KPC-positive
and ESBL-positive strain.
A fact that deserves to be emphasized is that these exper-
iments cannot be performed with bacterial cells at the sta-
tionary growth phase. This ﬁnding is understandable given
the mechanism of action of cephalosporins; like all b-lactam
antibiotics they require the binding to penicillin-binding pro-
teins (PBPs) during transpeptidation, which efﬁciently hap-
pens during active bacterial replication (exponential growth
phase) [19].
Although a few previous studies have evaluated the effect
of cephalosporins upon Gram-negative bacilli using FC, none
0.00E+00 
5.00E+05 
1.00E+06 
1.50E+06 
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CEFOTAXIME ( g/mL) CEFTAZIDIME ( g/mL) 
C
FU
/m
L 
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ESBL-negative
Cephalosporins 
associated to CLA 
FIG. 2. Number of CFU per ml of a repre-
sentative example of an ESBL-positive (Klebsiel-
la pneumoniae ID number: 767873) and an
ESBL-negative strain (Escherichia coli ID num-
ber: 770522) after 60 min exposure to cefo-
taxime (1, 2, 4 mg/L) or ceftazidime (4, 8 and
16 mg/L) alone and associated with clavulanic
acid ( 1 ). The difference between the CFU
numbers after exposure to the cephalosporins
alone and associated with CLA were statisti-
cally signiﬁcant only in the case of ESBL-posi-
tive strains (p <0.05).
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of them reported the effect of its association with CLA in
order to detect the presence of ESBLs [19–25].
The estimated costs for consumables and reagents used
for this new method for ESBL detection is rather low,
around 2.5€ per sample (per microorganism) screened with-
out taking into account the costs of the FC equipment and
technician. However, such apparatus is frequently found in
most hematology/immunology laboratories and could cer-
tainly be shared by microbiologists.
The FC assay herein described is a phenotype test, which
unlike the genotypic test, might be more suitable for routine
use. The PCR-based test might give a negative result with
mutations and has the disadvantage of being time consuming.
This is not the case for MALDI TOF MS, but this technique
still needs to be validated for susceptibility testing.
In conclusion, this novel FC assay is a promising method
that might be used in the clinical microbiology laboratory
during daily routine. Quantitative analysis and simplicity and
cost-effectiveness are advantages of this method. Moreover,
it reduces the waiting time for results. Despite the impera-
tive previous step of cell incubation until the exponential
phase is reached (1.5h), with our FC assay, results can be
obtained in 3 h (from the minimum of 3 h to a maximum of
20 h). Furthermore, the approach hereby reported has the
important advantage of easily integrating other antibiotic
and/or inhibitor associations, in order to identify promptly
and accurately other enzyme producing strains whose emer-
gence might represent a threat to the hospital or general
community. The described FC assay is an excellent alterna-
tive to the routine susceptibility testing assays for ESBL
detection.
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